26 results were returned
COVID-19 presents an unprecedented challenge to the global life sciences industry. Members of our International Life Sciences & Healthcare team, lawyers who have a wealth of hands-on experience and strong relationships ...
The Legal 500: Pharmaceutical Advertising Guide 2021 is a practical cross-border insight into pharmaceutical advertising, with contributing editor Sally Shorthose.
The Healthcare Services Bill (the "Bill") was passed on 6 January 2020, replacing the Private Hospitals and Medical Clinics Act ("PHMCA"), which was last amended in 1999. The Bill seeks to strengthen the safeguards for ...
On 22 May 2018, the Health Sciences Authority (the "HSA") issued a press release announcing changes to the regulatory process for medical devices ("MDs").
Bird & Bird has advised publicly traded Australian Elixinol Global Limited on the acquisition of leading German CBD company, CannaCare Health GmbH, Hamburg, by a Dutch subsidiary.
The Bill of the Law on the organization and transformation of the French healthcare system at the French parliament, adoption of the final version is expected for the end of July.
On 17 April 2019, the European Parliament approved, by a large majority, an amendment of the Regulation on Supplementary Protection Certificates ("SPCs").
In response to the COVID-19 pandemic, the Australian Federal Minister for Health has exercised his power under section 41GS of the Therapeutic Goods Act 1989 (Cth) (the Act) to exempt certain medical devices from the ...
The Therapeutic Goods Administration (TGA) has been monitoring and taking action against individuals and companies capitalising on the current pandemic to market and sell products that claim to prevent or cure COVID-19.
The Chambers & Partners Pharmaceutical Advertising Global Practice Guide 2018 is now available online. The UK chapter has been written by Bird & Bird’s Sally Shorthose and Sarah Faircliffe,